$1.86
3.33% yesterday
Nasdaq, Nov 25, 09:47 pm CET
ISIN
US69404D1081
Symbol
PACB
Sector
Industry

Pacific Biosciences of California, Inc. Stock price

$1.85
+0.08 4.52% 1M
-0.02 1.07% 6M
-7.96 81.14% YTD
-6.59 78.08% 1Y
-21.54 92.09% 3Y
-3.26 63.80% 5Y
-5.16 73.61% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.05 2.78%
ISIN
US69404D1081
Symbol
PACB
Sector
Industry

Key metrics

Market capitalization $506.65m
Enterprise Value $955.56m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 5.52
P/S ratio (TTM) P/S ratio 2.93
P/B ratio (TTM) P/B ratio 1.12
Revenue growth (TTM) Revenue growth 2.14%
Revenue (TTM) Revenue $173.15m
EBIT (operating result TTM) EBIT $-288.64m
Free Cash Flow (TTM) Free Cash Flow $-239.61m
Cash position $471.84m
EPS (TTM) EPS $-1.46
P/E forward negative
P/S forward 3.26
EV/Sales forward 6.15
Short interest 21.30%
Show more

Is Pacific Biosciences of California, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Pacific Biosciences of California, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Pacific Biosciences of California, Inc. forecast:

7x Buy
44%
9x Hold
56%

Analyst Opinions

16 Analysts have issued a Pacific Biosciences of California, Inc. forecast:

Buy
44%
Hold
56%

Financial data from Pacific Biosciences of California, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
173 173
2% 2%
100%
- Direct Costs 164 164
33% 33%
94%
9.61 9.61
80% 80%
6%
- Selling and Administrative Expenses 92 92
38% 38%
53%
- Research and Development Expense 146 146
21% 21%
84%
-228 -228
20% 20%
-132%
- Depreciation and Amortization 60 60
211% 211%
35%
EBIT (Operating Income) EBIT -289 -289
6% 6%
-167%
Net Profit -394 -394
28% 28%
-228%

In millions USD.

Don't miss a Thing! We will send you all news about Pacific Biosciences of California, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Pacific Biosciences of California, Inc. Stock News

Negative
Seeking Alpha
14 days ago
Pacific Biosciences of California stock surged 50% since August despite a 24% YoY revenue decline and deteriorating gross margins due to increased costs and pricing pressures. Q3 revenue of $40 million missed analyst estimates, with SG&A expenses surpassing total revenue and gross profit margins remaining low at 28%. Pacific Biosciences has made significant cuts in R&D, which may harm long-term...
Positive
The Motley Fool
14 days ago
The rock star money manager is starting to roll with the rallying market.
Neutral
GlobeNewsWire
18 days ago
MENLO PARK, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences:
More Pacific Biosciences of California, Inc. News

Company Profile

Pacific Biosciences of California, Inc. engages in the development, manufacture and sale of an integrated platform for genetic analysis. Its products and services include PacBio sequel system, consumables, analytical software, and single molecule real-time (SMRT) compatible products. It operates through the following geographical segments: North America, Europe, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.

Head office United States
CEO Christian Henry
Employees 796
Founded 2000
Website www.pacb.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today